Evidence map›Paper›PMID 41298649›Full record

ArticleScientific reports2025

CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.

Yuhang Wang, Jiuhui Xu, Shouyan Deng, Kunkun Sun, Yaqi Wang, Tingting Ren, Xiaodong Tang, Jie Xu, Lu Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuhang Wang *Department of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China.
Jiuhui Xu *Department of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China.
Shouyan DengInstitutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Zhongshan-Xuhui Hospital, Fudan University, Shanghai, 200032, China.
Kunkun SunDepartment of Pathology, Peking University People's Hospital, Beijing, China.
Yaqi WangDepartment of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China.
Tingting RenDepartment of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China.
Xiaodong TangDepartment of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China. tangxiaodong@pkuph.edu.cn.
Jie XuInstitutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Zhongshan-Xuhui Hospital, Fudan University, Shanghai, 200032, China. jie_xu@fudan.edu.cn.
Lu XieDepartment of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China. xielu@pkuph.edu.cn.

Funding

National Outstanding Youth Science Fund Project of National Natural Science Foundation of China 82403417National Science and Technology Major Project No. 2024ZD0525800Natural Science Foundation of Beijing Municipality L234041Natural Science Foundation of Beijing Municipality No. 2127000356Natural Science Foundation of Beijing Municipality No. QY24058
6 · The paper itself

Abstract

CD3L1 (ITPRIPL1), a natural ligand of CD3ε, is implicated in tumor-immune interactions and is overexpressed in several solid tumors. However, its expression and functional significance in osteosarcoma and chordoma remain uncharacterized. This study aimed to evaluate CD3L1 expression in osteosarcoma and chordoma and assess its association with clinical features and outcomes. Formalin-fixed, paraffin-embedded tissue samples from 42 osteosarcoma and 20 chordoma patients were analyzed for CD3L1 expression using immunohistochemistry. Multiplex immunofluorescence staining was performed to evaluate immune cell infiltration in chordoma. Associations between CD3L1 expression and clinicopathological parameters were examined using chi-square tests, Fisher's exact test, and Kaplan-Meier survival analysis. CD3L1 was detected in 62.9% (39/62) of cases, with positivity rates of 59.6% in osteosarcoma and 70.0% in chordoma. CD3L1 expression was independent of patient age, sex, or tumor location but was significantly associated with chondroid stroma and prior PD-1 immunotherapy in osteosarcoma. In chordoma, higher CD3L1 expression correlated with increased infiltration of CD8

Indexed as

Bone NeoplasmsChordomaOsteosarcomaTumor MicroenvironmentAdolescentAdultAgedBiomarkers, TumorChildFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedYoung AdultBiomarkers, TumorCD3L1 (ITPRIPL1)ChordomaImmunohistochemistryOsteosarcomaPrognosis

Identifiers

PMID41298649
PMCPMC12658221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.